Cargando…
Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports
BACKGROUND: Polypoidal choroidal vasculopathy (PCV) consists of polyps that potentially cause massive subretinal hemorrhage and their branching vascular network (BVN) of feeder vessels. Although conventional indocyanine green angiography (IA) has shown anti-vascular endothelial growth factor (VEGF)...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215629/ https://www.ncbi.nlm.nih.gov/pubmed/30390650 http://dx.doi.org/10.1186/s12886-018-0952-6 |
_version_ | 1783368179783827456 |
---|---|
author | Iesato, Yasuhiro Tanaka, Masaaki Murata, Masako Kitahara, Junya Hirano, Takao Kurenuma, Taihei Yoshida, Noriko Murata, Toshinori |
author_facet | Iesato, Yasuhiro Tanaka, Masaaki Murata, Masako Kitahara, Junya Hirano, Takao Kurenuma, Taihei Yoshida, Noriko Murata, Toshinori |
author_sort | Iesato, Yasuhiro |
collection | PubMed |
description | BACKGROUND: Polypoidal choroidal vasculopathy (PCV) consists of polyps that potentially cause massive subretinal hemorrhage and their branching vascular network (BVN) of feeder vessels. Although conventional indocyanine green angiography (IA) has shown anti-vascular endothelial growth factor (VEGF) agents and/or photodynamic therapy (PDT) to successfully induce polyp closure, the BVN appears resistant to these therapies and serves as the origin of recurrent active polyps. Recently introduced optical coherence tomography angiography (OCT-A) enables more frequent angiographic evaluation of polyps and the BVN than does conventional IA since it does not require intravenous fluorescent dye injection and is thus considered non-invasive. CASE PRESENTATION: Case 1. A 70-year-old male with PCV in his left eye suffered from vision deterioration (20/40) due to persistent subretinal fluid despite 42 intravitreal injections of ranibizumab (IVRs) over 5 years and 7 months. PDT was performed as an adjunct therapy 3 days after the 43rd IVR. IA at 3 months after PDT showed successful polyp closure but persisting BVN. However, more frequent evaluation with OCT-A starting at 1 week after PDT demonstrated complete regression of both the BVN and polyp. OCT-A at every subsequent outpatient visit depicted gradual re-perfusion of the BVN and the restoration of most of its original network at 3 months, which was compatible with IA findings. Neither OCTA nor IA revealed polyp recurrence at 3 months. Case 2. A 65-year-old female suffering from left vision deterioration due to PCV underwent 5 intravitreal injections of aflibercept. Since her subretinal fluid persisted, the treatment was switched to a combination of IVR and PDT. OCT-A revealed marked regression of the BVN and polyp at 2 weeks, but the BVN had regained its original shape at 2 months without any sign of polyp recurrence. CONCLUSIONS: Differently from previous observations obtained by IA alone, more frequent non-invasive OCT-A examination revealed complete but transient regression of the BVN just after combination therapy with IVR and PDT. |
format | Online Article Text |
id | pubmed-6215629 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-62156292018-11-08 Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports Iesato, Yasuhiro Tanaka, Masaaki Murata, Masako Kitahara, Junya Hirano, Takao Kurenuma, Taihei Yoshida, Noriko Murata, Toshinori BMC Ophthalmol Case Report BACKGROUND: Polypoidal choroidal vasculopathy (PCV) consists of polyps that potentially cause massive subretinal hemorrhage and their branching vascular network (BVN) of feeder vessels. Although conventional indocyanine green angiography (IA) has shown anti-vascular endothelial growth factor (VEGF) agents and/or photodynamic therapy (PDT) to successfully induce polyp closure, the BVN appears resistant to these therapies and serves as the origin of recurrent active polyps. Recently introduced optical coherence tomography angiography (OCT-A) enables more frequent angiographic evaluation of polyps and the BVN than does conventional IA since it does not require intravenous fluorescent dye injection and is thus considered non-invasive. CASE PRESENTATION: Case 1. A 70-year-old male with PCV in his left eye suffered from vision deterioration (20/40) due to persistent subretinal fluid despite 42 intravitreal injections of ranibizumab (IVRs) over 5 years and 7 months. PDT was performed as an adjunct therapy 3 days after the 43rd IVR. IA at 3 months after PDT showed successful polyp closure but persisting BVN. However, more frequent evaluation with OCT-A starting at 1 week after PDT demonstrated complete regression of both the BVN and polyp. OCT-A at every subsequent outpatient visit depicted gradual re-perfusion of the BVN and the restoration of most of its original network at 3 months, which was compatible with IA findings. Neither OCTA nor IA revealed polyp recurrence at 3 months. Case 2. A 65-year-old female suffering from left vision deterioration due to PCV underwent 5 intravitreal injections of aflibercept. Since her subretinal fluid persisted, the treatment was switched to a combination of IVR and PDT. OCT-A revealed marked regression of the BVN and polyp at 2 weeks, but the BVN had regained its original shape at 2 months without any sign of polyp recurrence. CONCLUSIONS: Differently from previous observations obtained by IA alone, more frequent non-invasive OCT-A examination revealed complete but transient regression of the BVN just after combination therapy with IVR and PDT. BioMed Central 2018-11-03 /pmc/articles/PMC6215629/ /pubmed/30390650 http://dx.doi.org/10.1186/s12886-018-0952-6 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Iesato, Yasuhiro Tanaka, Masaaki Murata, Masako Kitahara, Junya Hirano, Takao Kurenuma, Taihei Yoshida, Noriko Murata, Toshinori Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports |
title | Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports |
title_full | Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports |
title_fullStr | Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports |
title_full_unstemmed | Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports |
title_short | Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports |
title_sort | complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215629/ https://www.ncbi.nlm.nih.gov/pubmed/30390650 http://dx.doi.org/10.1186/s12886-018-0952-6 |
work_keys_str_mv | AT iesatoyasuhiro completeregressionofbranchingvascularnetworkinpolypoidalchoroidalvasculopathybyranibizumabandphotodynamictherapytwocasereports AT tanakamasaaki completeregressionofbranchingvascularnetworkinpolypoidalchoroidalvasculopathybyranibizumabandphotodynamictherapytwocasereports AT muratamasako completeregressionofbranchingvascularnetworkinpolypoidalchoroidalvasculopathybyranibizumabandphotodynamictherapytwocasereports AT kitaharajunya completeregressionofbranchingvascularnetworkinpolypoidalchoroidalvasculopathybyranibizumabandphotodynamictherapytwocasereports AT hiranotakao completeregressionofbranchingvascularnetworkinpolypoidalchoroidalvasculopathybyranibizumabandphotodynamictherapytwocasereports AT kurenumataihei completeregressionofbranchingvascularnetworkinpolypoidalchoroidalvasculopathybyranibizumabandphotodynamictherapytwocasereports AT yoshidanoriko completeregressionofbranchingvascularnetworkinpolypoidalchoroidalvasculopathybyranibizumabandphotodynamictherapytwocasereports AT muratatoshinori completeregressionofbranchingvascularnetworkinpolypoidalchoroidalvasculopathybyranibizumabandphotodynamictherapytwocasereports |